THANK YOU FOR SUBSCRIBING


Doron Aspitz, CEOThat’s where Verix can help.
Verix provides dedicated vertical analytic solutions to provide timely, focused, must-have insights for better, more creative, and efficient decision making.
“We take pride in the explainability inherent in our solution that allows users at all levels to understand the processes, the insights, and the recommendations,” says Doron Aspitz, the CEO of Verix. “One modality is small-wins—implement for one brand and show actual business results, real ROI. Nothing convinces users more than a solution that brings value.”
Verix offers an innovative, robust AI/ML platform to streamline pharma, biotech, and biomed commercial operations processes. Various use case applications, powered by AI/ML models, can be easily implemented on top of the Verix platform, offering a substantially shorter time-to-value. In addition, the platform’s machine learning models continuously incorporate new learnings and can be re-used time and again with the latest input. This is unlike the common one-and-done models that are designed for a specific situation and lose relevancy as circumstances change.
The platform’s architecture consists of three layers: Customer Data Platform (CDP), Decision Engine, and Workflow Generator. While CDP is a robust platform holding a rich set of predictive attributes about each account in the relevant therapeutic universe along with ML-based micro-segments capabilities, the Decision Engine supports predictive models dedicated to automate specific business needs.
“Verix has vertical focus and domain expertise to build accurate pharma specific models and algorithms that address common business questions and problems life-science companies have,” states Aspitz. “Verix’s cutting edge AI/ ML technology is dynamic, trustworthy, and scalable. It provides transparency to all business and data users that handle commercial processes.”
As an example, Verix has become a gold standard for AI/ML at Novartis US Oncology. Based on the dramatic proven results achieved by using Verix platform, Novartis has expanded from POC to ten oncology brands in 15 months! There has been a more than 25 percent increase in leading KPIs, including new scripts, a 20 percent increase in HCP Engagements, a four percent increase in new writers, and a six percent decrease in churn.![]()
We take pride in the explainability inherent in our solution that allows users at all levels to understand the processes, the insights, and the recommendations
In another case, GSK selected Verix after a successful POC compared to several other vendors’ solutions. Strong collaboration between Verix and GSK led to the co-development of ML models, targeting and segmentation of three oncology brands, and channel optimization. The results show a clear advantage over existing methods and competing solutions.
Such has been the prowess that Verix has garnered over the years by delivering platform-based solutions. Founded by two experts in Artificial Intelligence solutions for Commercial Operations, the company has been instrumental in helping clients grow their businesses by delivering the proactive insights needed to thrive in today’s global economy.
Company
Verix
Management
Doron Aspitz, CEO
Description
Verix offers an innovative, robust AI/ML platform to streamline Pharma, Biotech, and Biomed commercial operations processes. Use case applications (AI/ML models) can be easily implemented on top of its platform, offering a substantially shorter time-to-value.
SANTA CLARA, Calif., -- Verix, the leading provider of AI commercial operations enhancement platforms for the pharmaceutical industry, announced today the launch of a new AI patient finder analysis for its Tovana platform. Tovana is an AI/ML and analytics-powered commercial optimization platform that provides life science organizations with the ability to harness all the available HCP (health care provider), patient, and market data, while providing continuous, reliable and explainable data-driven insights so pharma companies can optimize their execution and drive growth.
Tovana leverages the power of AI to process anonymized claim level patient longitudinal data, producing in-depth, accurate information at a fraction of the time and price as traditional approaches. This data helps pharma companies streamline their sales and business process and ensure the right patients are getting the right drugs, at the right time. The platform automatically ingests new data as it arrives, so it is constantly providing up-to-date insights. Tovana optimizes execution, enhances transparency, and enables cross-team collaboration. Top industry players are already using the Tovana platform, including GSK, Bayer, Novartis, and Roche.
The "patient finder analysis," allows for the early identification of new patients with rare diseases based on the AI matching of previous patients with similar journeys. This feature can reduce treatment discontinuity by providing insights into previous - and similar - patient journeys, as well as streamlined operations and increased efficiency by leveraging advanced analytics and data sources for patient optimization.
Verix has already developed and implemented successful additional cutting edge industry use cases on top of the Tovana platform, such as Dynamic Targeting and Segmentation, Bottom-Up Forecasting, Channel Mix Optimization, and Therapeutic Landscape Analysis. For pharma companies, these use cases optimize customer engagement and strengthen market positioning, leading to significant revenue increase. In addition, with no-code capabilities, Tovana allows users to develop their own models or utilize out-of-the-box tried and true use cases.
"As we continue to grow, serving more and more customers, we understand the strategic value of building out the category-leading AI capabilities of our platform," said Doron Aspitz, CEO of Verix. "Tovana's patient finder feature has the ability to revolutionize the way rare diseases are treated. We know that Tovana's use cases fill an important gap in pharmaceutical analytics and look forward to continuing to build out the platform's AI-driven capabilities in the future."